Boehringer Ingelheim Acquires Abexxa to Expands its Immuno-oncology Research

September 22, 2021 Auto Bot Acquire, Boehringer Ingelheim, M&A 0

Shots:

  • The acquisition includes upfront, milestones, and other consideration payments. Abexxa will continue to operate in the Arlington
  • The acquisition will allow Boehringer to access Abexxa’s expertise and capabilities in targeting cancer-specific proteins by using its technology to develop cancer immunotherapies and Abs for solid cancers
  • The acquisition also bolsters Boehringer’s commitment to identifying the tumor-antigen & other ways for targeting intracellular antigens. Abexxa has developed TCR like Abs that can be used to disrupt the NKG2A: HLA-E immune checkpoint axis in oncology

Click here to­ read full press release/ article | Ref: Businesswire | Image: MDDI

The post Boehringer Ingelheim Acquires Abexxa to Expands its Immuno-oncology Research first appeared on PharmaShots.